Previous 10 | Next 10 |
Flexion Therapeutics (FLXN) trades 3.6% higher after hours on reporting prelim ZILRETTA net sales of ~$24.6M for the quarter ended Mar.31, 2021."“While the impacts of the COVID-19 pandemic continue to affect patient flows, barring any unforeseen resurgence or outbre...
First-quarter ZILRETTA® net sales estimated to be approximately $24.6 million 2021 full-year ZILRETTA net sales anticipated to be in the range of $120 million to $130 million and total operating expenses expected between $195 million to $205 m...
BURLINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20 th Annual Healthcare Conference. The virtu...
Flexion Therapeutics (FLXN) announces the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safety and tolerability of FX301 administered as a single-dose, popliteal fossa block in patients undergoing the surgical procedure bunionectomy.FX301 is a l...
FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing...
Flexion Therapeutics is one of many biopharmas whose marketing rollouts were impacted in a negative way in 2020 by the pandemic. 2021 should see those headwinds ease and sales growth gain traction. So are the shares of this frustrating small-cap concern a buy? A full analysis and ...
Aspira Women's Health (AWH) has extended the post-market gains with a ~12.2% rise in the pre-market as analysts weigh in on its new agreement to develop an early detection test for ovarian cancer.“We support the notion of the team taking another big swing and working to ...
The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Flexion Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtua...
Image source: The Motley Fool. Flexion Therapeutics Inc (NASDAQ: FLXN) Q4 2020 Earnings Call Mar 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Flexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...